Physician profile
Alyssa Golas
NPI 1841449808
$2,103.36
in general payments reported to CMS, 2019-2025
16 companies · $188 in 2025
The $188 reported for 2025 was less than what a typical Plastic and Reconstructive Surgery provider received nationally (typical 2025 total: $445).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $240 · 2020: $20.77 · 2022: $900 · 2023: $558 · 2024: $197 · 2025: $188.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $943.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $943.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ethicon US, LLC | $476.88 | 2022-2023 | Echelon Endopath |
| Ethicon INC. | $450.00 | 2022 | |
| Innocoll Pharmaceuticals Limited | $394.18 | 2023 | Xaracoll |
| Allergan, INC. | $239.53 | 2019 | |
| Abbvie INC. | $205.15 | 2024-2025 | |
| Ambu INC. | $117.88 | 2023 | |
| Solventum Corporation | $46.18 | 2024-2025 | V.A.C.Ulta, Prevena, V.A.C.Instill |
| Kerecis Limited | $28.55 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide |
| Becton, Dickinson and Company | $22.90 | 2024 | Phasix Mesh |
| Acell, INC. | $20.77 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $18.97 | 2024 | Fasenra |
| Organogenesis INC. | $18.89 | 2023 | Puraply |
| Avadel Cns Pharmaceuticals, LLC | $16.83 | 2025 | Lumryz |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.36 | 2024 | Ofev |
| Integra Lifesciences Corporation | $15.29 | 2025 | Integra, Surgimend, Integra Dermal Regeneration Template |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pacira Pharmaceuticals Incorporated | $15.00 | 2024 | Exparel |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alyssa Golas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.